Research programme: adenosine A2A receptor antagonists - Pharmacopeia

Drug Profile

Research programme: adenosine A2A receptor antagonists - Pharmacopeia

Alternative Names: PS-246518

Latest Information Update: 12 Oct 2009

Price : $50

At a glance

  • Originator Pharmacopeia Drug Discovery
  • Class
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 12 Oct 2009 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)
  • 12 Oct 2009 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route)
  • 23 Dec 2008 Pharmacopeia has been acquired by Ligand Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top